Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Analysts

Definium Therapeutics, Inc. (NASDAQ:DFTX) has earned a consensus rating of “Buy” from the fifteen research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $37.9231.

DFTX has been the topic of a number of research analyst reports. Stifel Nicolaus set a $30.00 price target on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Thursday, April 16th. Wolfe Research initiated coverage on shares of Definium Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 price target on the stock. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price target on shares of Definium Therapeutics in a report on Thursday, April 23rd. Canaccord Genuity Group reiterated a “buy” rating and issued a $38.00 price target on shares of Definium Therapeutics in a report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Tuesday, April 21st.

Hedge Funds Weigh In On Definium Therapeutics

A number of hedge funds have recently made changes to their positions in DFTX. Commodore Capital LP boosted its holdings in shares of Definium Therapeutics by 10.5% in the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after purchasing an additional 475,000 shares during the last quarter. Orbimed Advisors LLC acquired a new position in shares of Definium Therapeutics in the 3rd quarter valued at $4,337,000. Rosalind Advisors Inc. raised its stake in shares of Definium Therapeutics by 78.6% in the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after acquiring an additional 330,000 shares during the period. Two Sigma Investments LP raised its stake in shares of Definium Therapeutics by 424.9% in the 3rd quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock valued at $3,495,000 after acquiring an additional 239,965 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Definium Therapeutics by 11.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after acquiring an additional 198,878 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Stock Up 0.2%

Shares of NASDAQ DFTX opened at $24.48 on Friday. Definium Therapeutics has a 1 year low of $6.34 and a 1 year high of $26.25. The firm’s 50 day moving average price is $22.61 and its 200 day moving average price is $18.32. The firm has a market cap of $2.44 billion, a P/E ratio of -9.83 and a beta of 2.37. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). As a group, sell-side analysts anticipate that Definium Therapeutics will post -2.3 earnings per share for the current year.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.